Antiparticula
Madmaxista
Que trolleo más majo.
⚡⚡(HILO OFICIAL) : CRISIS DEL cobi19 ☣SARS-CoV2☣
- Autor del tema ULTRAPACO
- Fecha de inicio
Oso Amoroso
Madmaxista
- Desde
- 29 Dic 2012
- Mensajes
- 3.304
- Reputación
- 10.518
Tu eres de los que besaban los culos de los tertulianos de la TV alla por Febrero repitiendo su mantra de que era todo mentira y ahora vais dando lecciones al resto de la gente?
Visilleras
de Complutum
- Desde
- 25 Jul 2009
- Mensajes
- 50.879
- Reputación
- 208.035
Mecanosfera
Madmaxista
No. Yo me he comido en vivo y en directo un Rebrote supuestamente letal y horripilante en Galicia hace un par se semanas y se de lo que me hablo. No doy lecciones de nada, pero me gustaria que se publicasen a diario las muertes por absolutamente todas las causas (infartos, cancer, gripe, accidente...) para que asi pudiesemos poner en perspectiva la gravedad de esta "segunda ola".
Rubish21
Madmaxista
- Desde
- 21 Nov 2016
- Mensajes
- 1.040
- Reputación
- 5.957
Es muy dolido ver estos números y ver los nuestros, vamos por 2000 y pico contagios y encima la culpa la tienen los demás porque vetan a nuestro país. ¿Qué esperan?
Hoy viene el señor Simón después de sus vacaciones, en el momento mas delicado económicamente y sanitariamente, para con la chulería que le caracteriza, decir que mejor que no vengan belgas, que los aeropuertos son un coladero. Y.... eso no lo sabían hace ya meses, no podían hacer test?
Es muy indignante ver a los italianos como han aprendido algo y nosotros que mires por donde mires es dramático.
Carlx
Madmaxista
- Desde
- 22 Feb 2012
- Mensajes
- 5.630
- Reputación
- 7.278
Retrasao
ese muslo despierta a un muerto, una mujer para mi harenEspaña se rezaga y ocupa ya el puesto 23 en la práctica de test pese a los rebrotes
/cloudfront-eu-central-1.images.arcpublishing.com/larazon/TOCZBTA6HRE7BGZBPSDCVRAVJE.JPG)
Las estadísticas sitúan a nuestro país lejos de la cabeza en pruebas por millón de habitantes Pese al bajo número de detecciones practicadas, sigue en el «top ten» mundial de personas infectadas
Pista: La noticia es lo de menos...
carvil
Madmaxista
- Desde
- 11 Dic 2008
- Mensajes
- 6.906
- Reputación
- 14.068
Moderna Inc. said the pivotal study of its experimental cobi19 vaccine began Monday, with the first subjects receiving doses.
Researchers plan to enroll 30,000 people across the U.S. in the last-stage, or phase 3, trial of the Moderna vaccine candidate. Results, which government health officials said could come by November, will determine whether two doses protect against symptomatic el bichito-19, and whether it should be cleared for widespread use.
The Cambridge, Mass., company also received an additional commitment of up to $472 million from the federal government to support the large study, on top of the $483 million in funding earlier in the year for development, testing and preparations to manufacture at large scale.
Moderna, which codesigned the vaccine with the National Institute of Allergy and Infectious Diseases, previously reported promising results of the first study of the vaccine, showing it induced immune responses and was generally safe in a small number of people.
The new phase 3 trial, titled Cove, is being conducted at nearly 90 sites in the U.S., including many in states such as Texas where the bichito has surged in recent weeks.
No vaccine has proven to work safely against the cobi19. Many vaccines developed to target other pathogens have failed in testing, including in phase 3 trials.
U.S. officials said Monday it was the fastest time from the design of a new vaccine to the start of phase 3 testing in the U.S. NIAID researchers helped design the vaccine, code-named mRNA-1273, in January after the genetic code of the bichito was posted to a public database.
"Yes, we're going fast, but no, we are not going to compromise safety or efficacy," National Institutes of Health Director Francis Collins said on a conference call with reporters Monday. NIAID is part of the NIH.
The start of the pivotal Moderna vaccine trial is the latest sign that the most advanced cobi19 vaccine candidates are moving into the final stages of testing, and could be ready for wider use before year's end if results are positive.
A vaccine co-developed by the University of Oxford and AstraZeneca PLC started a large study in May in the U.K., and is due to enter a phase 3 study in the U.S. in August. A vaccine co-developed by Pfizer Inc. and BioNTech SE is due to start phase 3 testing this week.
Another company expected to be a major player in the vaccine hunt, Johnson & Johnson, is scheduled to start the first U.S. human study of its experimental shot Monday. A larger, phase 3 study of J&J's vaccine may start in September.
Moderna hopes its large study, which is being conducted in collaboration with the NIH, will yield positive results and possible vaccine availability in the fall, with J&J aiming for similar milestones by early 2021.
In the new Moderna vaccine study, about half of the adult volunteers will receive two shots of the vaccine four weeks apart, while the other half will get two doses of a placebo.
Starting two weeks after the second dose, researchers will track whether the rate of symptomatic el bichito-19 disease in the vaccinated group is lower than in unvaccinated people.
NIAID Director Anthony Fauci said researchers may learn in November or December whether the Moderna vaccine works, but the answer could come sooner, depending on infection rates in the places where the study is being conducted.
Moderna has been manufacturing doses even before getting an answer on efficacy, but if it gets a green light from the government for wider user, it is unlikely there will be enough doses for all Americans right away.
Chief Executive Stéphane Bancel said there could be enough doses initially for "millions and millions" of people, which could be prioritized for at-risk groups like health-care workers.
The NIH and the Centers for Disease Control and Prevention have asked a National Academy of Medicine committee to come up with a plan for equitable allocation of any effective el bichito-19 vaccines.
Moderna expects a wider rollout of the vaccine next year if the study is positive. It says it is on track to deliver about 500 million doses a year, and possibly up to one billion doses, starting in 2021.
Salu2
Researchers plan to enroll 30,000 people across the U.S. in the last-stage, or phase 3, trial of the Moderna vaccine candidate. Results, which government health officials said could come by November, will determine whether two doses protect against symptomatic el bichito-19, and whether it should be cleared for widespread use.
The Cambridge, Mass., company also received an additional commitment of up to $472 million from the federal government to support the large study, on top of the $483 million in funding earlier in the year for development, testing and preparations to manufacture at large scale.
Moderna, which codesigned the vaccine with the National Institute of Allergy and Infectious Diseases, previously reported promising results of the first study of the vaccine, showing it induced immune responses and was generally safe in a small number of people.
The new phase 3 trial, titled Cove, is being conducted at nearly 90 sites in the U.S., including many in states such as Texas where the bichito has surged in recent weeks.
No vaccine has proven to work safely against the cobi19. Many vaccines developed to target other pathogens have failed in testing, including in phase 3 trials.
U.S. officials said Monday it was the fastest time from the design of a new vaccine to the start of phase 3 testing in the U.S. NIAID researchers helped design the vaccine, code-named mRNA-1273, in January after the genetic code of the bichito was posted to a public database.
"Yes, we're going fast, but no, we are not going to compromise safety or efficacy," National Institutes of Health Director Francis Collins said on a conference call with reporters Monday. NIAID is part of the NIH.
The start of the pivotal Moderna vaccine trial is the latest sign that the most advanced cobi19 vaccine candidates are moving into the final stages of testing, and could be ready for wider use before year's end if results are positive.
A vaccine co-developed by the University of Oxford and AstraZeneca PLC started a large study in May in the U.K., and is due to enter a phase 3 study in the U.S. in August. A vaccine co-developed by Pfizer Inc. and BioNTech SE is due to start phase 3 testing this week.
Another company expected to be a major player in the vaccine hunt, Johnson & Johnson, is scheduled to start the first U.S. human study of its experimental shot Monday. A larger, phase 3 study of J&J's vaccine may start in September.
Moderna hopes its large study, which is being conducted in collaboration with the NIH, will yield positive results and possible vaccine availability in the fall, with J&J aiming for similar milestones by early 2021.
In the new Moderna vaccine study, about half of the adult volunteers will receive two shots of the vaccine four weeks apart, while the other half will get two doses of a placebo.
Starting two weeks after the second dose, researchers will track whether the rate of symptomatic el bichito-19 disease in the vaccinated group is lower than in unvaccinated people.
NIAID Director Anthony Fauci said researchers may learn in November or December whether the Moderna vaccine works, but the answer could come sooner, depending on infection rates in the places where the study is being conducted.
Moderna has been manufacturing doses even before getting an answer on efficacy, but if it gets a green light from the government for wider user, it is unlikely there will be enough doses for all Americans right away.
Chief Executive Stéphane Bancel said there could be enough doses initially for "millions and millions" of people, which could be prioritized for at-risk groups like health-care workers.
The NIH and the Centers for Disease Control and Prevention have asked a National Academy of Medicine committee to come up with a plan for equitable allocation of any effective el bichito-19 vaccines.
Moderna expects a wider rollout of the vaccine next year if the study is positive. It says it is on track to deliver about 500 million doses a year, and possibly up to one billion doses, starting in 2021.
Salu2
Pues tienes razón. En siete meses volvemos a marzo, cierto es.
DR TRUTH
Libertad o Muerte Gnóstico Antiposmoderno
- Desde
- 26 Jul 2020
- Mensajes
- 1.335
- Reputación
- 4.252
hay cientificos honestos como el Dr. Stoian Alexov que dicen que NO SE HAN ENCONTRADO ANTICUERPOS ESPECÍFICOS CONTRA EL SARS-COV-2, Y LOS TEST DE DETECCIÓN NO SIRVEN PARA NADA, con lo cual TODA ESPECULACIÓN SOBRE MUERTES POR el bichito, NO CONFIRMADAS MEDIANTE AUTOPSIAS, SÓLO SIRVEN PARA ALIMENTAR LA HISTERIA COLECTIVA.
NO HAY NI UNA SOLA AUTOPSIA QUE DEMUESTRE QUE EL cobi19 «POR SI SOLO» HAYA PROVOCADO ALGUNA MUERTE; ES MÁS: NI SIQUIERA HAY PRUEBAS DE QUE EL bichito EXISTA.
CURIOSAMENTE, UNA DE LAS INNUMERABLES FORMAS EN QUE LA OMS CREÓ ESTE CAOS FUE PROHIBIENDO HACER AUTOPSIAS --todo huele a podrido, instituciones y medios estan perdiendo la credibilidad cada segundo que pasa----
NO HAY NI UNA SOLA AUTOPSIA QUE DEMUESTRE QUE EL cobi19 «POR SI SOLO» HAYA PROVOCADO ALGUNA MUERTE; ES MÁS: NI SIQUIERA HAY PRUEBAS DE QUE EL bichito EXISTA.
CURIOSAMENTE, UNA DE LAS INNUMERABLES FORMAS EN QUE LA OMS CREÓ ESTE CAOS FUE PROHIBIENDO HACER AUTOPSIAS --todo huele a podrido, instituciones y medios estan perdiendo la credibilidad cada segundo que pasa----
Caronte el barquero
Será en Octubre
Saco la bola de cristal, apuesto al cierre de discos en Coruña en breve............. y me voy a cenar a la playa ( unos bocatas lonchafinistas).
Me lo ha dicho un pajarito.
Me lo ha dicho un pajarito.
rejon
Madmaxista
- Desde
- 3 Ene 2015
- Mensajes
- 127.604
- Reputación
- 226.955
Esta es la actualización del gráfico de infectados con inicio en los últimos 7 días. Los datos son de sanidad .. La tendencia es elaboración propia. Sobran las palabras... 
Leon S. Kennedy
Madmaxista
- Desde
- 7 Jul 2011
- Mensajes
- 15.633
- Reputación
- 32.206
Es un orate. Y ya no sabe qué máscara ponerse cada vez que sale a contar nuevas mentiras, no da para más.
AzulyBlanco
Madmaxista
- Desde
- 25 May 2013
- Mensajes
- 12.655
- Reputación
- 49.548
Por supuesto que estaría bien que se publicasen esos datos diariamente.
Pero ahora mismo, en Madrid, que la situación está "bien", hay 27 personas en la UCI por cobi19. Sinceramente no creo que a finales de Julio, ni de este año, ni de ningún otro año, hubiese ni 5 personas en la UCI por gripe (influenza). Más de 120 personas hospitalizadas por un bichito respiratorio cuando estamos a 40 grados.
Pues eso, el cobi19 no será la peste negra, pero para tomarselo a broma, despues de lo pasado y lo visto, no me lo parece tampoco.
